Substance / Medication

Cysteamine

Overview

Active Ingredient
cysteamine
RxNorm CUI
3022

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Copper-cysteamine nanoparticles in cancer treatment: a systematic review.
Ejtema Mahsa, Chegeni Nahid, Langen Britta et al. · Cell Biol Toxicol · 2025
PMID: 41307760Meta-AnalysisFull text (PMC)
Efficacy and safety of cysteamine 5% cream for the management of melasma: a systematic review and meta-analysis of randomized controlled trials.
Mawu Ferra Olivia, Christopher Paulus Mario · Arch Dermatol Res · 2024
PMID: 39673630Meta-Analysis
Is cysteamine use effective in the treatment of melasma? A systematic review and meta-analysis.
Dos Santos-Neto Agenor Gomes, da Silva Ísis Carolline Valério, Melo Carlisson Ramos et al. · Dermatol Ther · 2022
PMID: 36285354Meta-Analysis
Efficacy and Safety of Topical Cysteamine in Corneal Cystinosis: A Systematic Review and Meta-Analysis.
Kaur Sukhmandeep, Sarma Phulen, Kaur Hardeep et al. · Am J Ophthalmol · 2021
PMID: 32888903Meta-Analysis
A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
Medic Goran, van der Weijden Miriam, Karabis Andreas et al. · Curr Med Res Opin · 2017
PMID: 28692321Meta-Analysis
Efficacy of overnight leave-on sandwich therapy with 5% cysteamine and ectoine cream compared to hydroquinone 4% cream for treatment of melasma: a double-blind randomized controlled trial.
Kusumawardani Arie, Murasmita Alamanda, Rosmarwati Ervina et al. · Acta Dermatovenerol Alp Pannonica Adriat · 2025
PMID: 40127492RCT
Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action.
Sachdev Mukta, Grimes Pearl E, Callender Valerie et al. · J Drugs Dermatol · 2024
PMID: 38306138RCT
Efficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma.
Khatri Khalil A, Abdullah Nurul Ain, Chia Steve et al. · J Drugs Dermatol · 2024
PMID: 38954613RCT
Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma.
Sepaskhah Mozhdeh, Karimi Fatemeh, Bagheri Zahra et al. · J Cosmet Dermatol · 2022
PMID: 35510765RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mercaptamine (substance)
SNOMED CT
373457005
UMLS CUI
C0010648
RxNorm CUI
3022

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.